Background/Objectives: Vitamin B 12 (B 12 ) deficiency is common in Indians and a major contributor to hyperhomocysteinemia, which may influence fetal growth, risk of type II diabetes and cardiovascular disease. The purpose of this paper was to study the effect of physiological doses of B 12 and folic acid on plasma total homocysteine (tHcy) concentration. Subjects/Methods: A cluster randomized, placebo-controlled, double-blind, 2 Â 3 factorial trial, using the family as the randomization unit. Results: From 119 families in the Pune Maternal Nutrition Study, 300 individuals were randomized. There was no interaction between B 12 and folic acid (P ¼ 0.14) in relation to tHcy concentration change and their effects were analyzed separately: B 0 vs. B 2 vs. B 10 ; and F 0 vs. F 200 . At 12 months, tHcy concentration reduced by a mean 5.9 (95% CI: À7.8, À4.1) mmol/l in B 2 , and by 7.1 (95% CI: À8.9, À5.4) mmol/l in B 10 , compared to nonsignificant rise of 1.2 (95% CI: À0.5, 2.9) mmol/l in B 0 . B 2 and B 10 did not differ significantly. In F 200 , tHcy concentration decreased by 4.8 (95% CI: À6.3, À3.3) mmol/l compared to 2.8 (95% CI: À4.3, À1.2) mmol/l in F 0 . Conclusion: Daily oral supplementation with physiological doses of B 12 is an effective community intervention to reduce tHcy. Folic acid (200 mg per day) showed no additional benefit, neither had any unfavorable effects.
Introduction
Hyperhomocysteinemia is a risk factor for cardiovascular disease (CVD) (Wald et al., 2002) , psychiatric disorders (dementia and Alzheimer's disease) (Smith, 2008) and in pregnancy for adverse outcomes including early pregnancy loss, birth defects and low birth weight (LBW) Selhub, 2008) . Low vitamin B 12 (B 12 ) status and hyperhomocysteinemia are common among Indians living in India (Refsum et al., 2001; Yajnik et al., 2006) , and those migrated abroad (Chambers et al., 2000; Chandalia et al., 2003) . This is largely due to B 12 deficiency, even with normal folate status, reflecting vegetarian food habits. In recent years, this has been particularly well documented from Pune, India (Refsum et al., 2001; Yajnik et al., 2006 Yajnik et al., , 2008 . In the Pune Maternal Nutrition Study (PMNS), maternal hyperhomocysteinemia predicted LBW (Yajnik et al., 2005) , and neurocognitive impairment in children (Bhate et al., 2008) , and low maternal B 12 with high erythrocyte folate predicted higher adiposity and higher insulin resistance in the offspring (Yajnik et al., 2008) . On the basis of these results, we propose that B 12 supplementation in women of childbearing age may be a simple and effective mass measure to lower the incidence of LBW, adiposity and insulin resistance and thus of type II diabetes and CVD, and also improve neurocognitive function of the children.
In an earlier 'proof of concept' trial (Yajnik et al., 2007) , we showed that high-dose oral B 12 supplementation (500 mg alternate day, for 6 weeks) reduced circulating total homocysteine (tHcy) concentrations. We report results of a randomized, placebo-controlled trial of B 12 supplementation on plasma homocysteine, using physiological doses over 12 months.
Methods

Participants
The participants were families from an 'extended' cohort of the PMNS. The PMNS methodology has been reported in detail by Rao et al. (2001) . In brief, 2675 married women of childbearing age, living in six rural villages near Pune city were recruited, and those who became pregnant were followed up. After the main study, we enrolled an additional 153 pregnant women from the same recruited sample to study the early fetal growth. They did not contribute to the main study, and nutritional and blood measurements were not available during pregnancy. Of these, 119 families remain in follow-up, and the child and parents (349 individuals) were invited to take part in this study.
The study was approved by the KEM Hospital Ethics Committee. Exclusion criteria were the following: unwillingness to participate, pregnancy, anemia (hemoglobin o9 g per 100 ml), already taking supplements containing iron, folic acid and/or B 12 for 10 or more days, or on treatment with drugs known to impair the absorption or utilization of folic acid or B 12 (for example, phenytoin, antacids). We obtained informed written consent from the parents and informed written assent from the children (mean age 9 years).
For blood collection (June to November 2006), the families were brought to the Research Centre, the evening before the study. A standard vegetarian dinner was provided, after which they rested. A fasting blood sample was collected in the morning.
Study design and intervention
The trial was double blinded. We planned to test three levels of B 12 supplementation (none, 2 and 10 mg) and each of these at two levels of folic acid supplementation (none and 200 mg), forming six groups (A ¼ (Figure 1 ). Randomization was computer-based. The unit of randomization was the family, making it a cluster-randomized trial. We stratified the families by the children's baseline plasma B 12 concentrations; those below and above the median value were equally distributed in six groups. Within each group, the statistician randomly allocated codes (A-F) to the participant families. The contents of the capsules were known only to the pharmacist until the end of the trial. The codes were revealed only after data analysis. The study capsules were manufactured in six different colors. The supplements were dispensed monthly in containers labeled with the participant's name and capsule group (A-F). All members of the family received the same colored capsules. The participants were advised to take one capsule orally, daily before breakfast. The number of dispensed capsules and those returned at each monthly home visit was counted to calculate the compliance. At each monthly home visit, we recorded adverse events and treatment of intercurrent illnesses, if any. Participants who took medicine containing folic acid and/or B 12 for more than 10 days were omitted from data analysis. The duration of supplementation was 12 months, and took place between April 2007 and March 2008. Laboratory analysis of the study medication at the beginning and end of the study period revealed similar potency of the capsules.
Measurements
Blood samples were collected at baseline and 4 and 12 months after supplementation and were measured in separate batches. The samples were collected in EDTA tubes, kept on ice and spun within 1 h (2500 g Â 15 min) and plasma aliquots were stored (À70 1C) until further analysis. Hemoglobin was measured within 1 h of blood collection on a Beckman Coulter Analyzer (A C .T diff; Miami, Florida).
Plasma creatinine was measured on an Alcyon 300 automated analyzer (Abbott Laboratories, Abbott Park, IL, USA) using Jaffe's method. Plasma B 12 and folate were measured by microbiological assay using a colistin sulfate-resistant strain of Lactobacillus leichmannii (Kelleher et al., 1987; Kelleher and Broin, 1991) and a chloramphenicol-resistant strain of Lactobacillus casei (Horne and Patterson, 1988; Tamura et al., 1990) , with inter-batch CV o8 and o7%, respectively. Plasma tHcy concentration was measured by fluorescence polarization immunoassay (Abbott Laboratories; CV o8%) (Shipchandler and Moore, 1995) . Height was measured to the nearest 0.1 cm using a wallmounted stadiometer (CMS Instruments, London, UK) and body weight to the nearest 0.005 kg (Conveigh, Electronic Instruments Ltd, Mumbai, India). Dietary intake of B 12 -and folate-rich foods was recorded by food frequency questionnaire in children at the beginning and end of 12 months.
Definitions
Compliance was defined as taking X80% of the dispensed capsules, hyperhomocysteinemia as plasma tHcy concentrations 415 mmol/l (in adults), 410 mmol/l (in children) (Refsum et al., 2004) , and B 12 and folate deficiency as concentrations o150 pmol/l (Refsum et al., 2001 ) and o7 nmol/l , respectively.
Statistical methods
The data are presented as mean and standard deviation (s.d.). Though B 12 and tHcy concentrations were not normally distributed, we used parametric tests for differences between group means, which are normally distributed as per the central limit theorem. We used analysis of variance to test the differences between supplementation groups, adjusting for the cluster design. There was no difference between clustered and unclustered analysis (statistically insignificant intraclass correlation). The change in the prevalence of hyperhomocysteinemia from baseline was tested by McNemar's test.
The change in plasma tHcy concentrations was adjusted for the baseline tHcy concentrations, age and gender. There was no significant interaction between the effects of B 12 and folic acid supplementation on change in plasma tHcy concentration (P ¼ 0.14; Figure 1 in Supplementary Information). Therefore, the effects of 2 and 10 mg B 12 supplementation were tested against no B 12 , combining the folic acid supplementation groups ( . The relative benefit for hyperhomocysteinemia was calculated by taking ratios of absolute benefit in different supplementation groups against non-supplemented group. The number needed to treat was calculated as the reciprocal of the absolute risk reduction for hyperhomocysteinemia at the end of 12 months. All analyses were conducted using Stata, version 7.0 (Stata Inc. College Station, TX, USA).
Results
Recruitment and participant flow
Of the 119 families (349 individuals) in the extended PMNS cohort, 307 individuals were willing to participate (88% response), 7 (1 pregnant, 6 anemic) were excluded and 300 (106 children, 93 fathers and 101 mothers) were randomized (Figure 1 ). During the intervention, one woman became pregnant and five participants received B 12 -containing medication (from family physician) and were excluded from the analysis. Three participants withdrew and one was lost to follow-up after collection of the 4-month sample; they were analyzed using the Last Observation Carried Forward method. Thus, the final analysis includes 294 participants (106 children, 92 fathers and 96 mothers). Table 1 shows the basic characteristics of the 300 participants. Seventy-two percent fathers, 48% mothers and 27% children were B 12 deficient, and 75% fathers, 35% mothers and 47% children were hyperhomocysteinemic. In contrast, only 14% fathers, 8% mothers and 2% children had folate deficiency. Baseline B 12 , folate and tHcy concentrations were similar in the different supplementation groups.
Baseline characteristics
Compliance Seventy-one percent (n ¼ 210) participants returned o20% of the dispensed capsules over 12 months and were defined as 'compliers'. Fourteen percent participants consumed 70-80%, 6% consumed 60-70%, another 6% consumed 50-60% and remaining 3% consumed o50% of the dispensed dose. The mean plasma tHcy concentration, decrease in plasma tHcy concentration and prevalence of hyperhomocysteinemia at 4 and 12 months were similar in the compliers (n ¼ 210) and noncompliers (n ¼ 84) (Table 1 in Supplementary Information). Overall compliance rates were similar at 4 and 12 months.
The frequency of consumption of folate-and B 12 -rich foods in children was similar at baseline and after 12 months.
Plasma B 12 and folate concentrations At baseline 48% participants were B 12 deficient. Plasma B 12 concentrations increased significantly in those who received B 12 supplements (Table 2) . At 12 months the rise was 64% in those who received 2 mg (B 2 ) and 119% in those who received 10 mg (B 10 ). In both groups this was similar to the rise (F 200 ) and by 18.8% in the group who did not (F 0 ). At baseline 8% participants were folate deficient; after 12 months this reduced to 0% in the supplemented and to 6% in the non-supplemented group.
Plasma total homocysteine concentration B 12 supplementation. Plasma tHcy concentrations decreased in the B 2 and B 10 groups, and showed little change in the B 0 group (Figure 2 , Table 2 ). The decrease was greater in those with higher baseline concentrations (r ¼ À0.6, P ¼ 0.000). We therefore adjusted the change in plasma tHcy concentrations for baseline concentrations. The change in plasma tHcy concentrations was not related to the baseline plasma B 12 and folate concentrations. The baseline-adjusted decrease was 5.9 (95% CI: À7.8, À4.1) mmol/l in the B 2 group and 7.1 (95% CI: À8.9, À5.4) mmol/l in the B 10 group (not significantly different). The B 0 group showed a nonsignificant rise of 1.2 (95% CI: À0.5, 2.8) mmol/l. Eighty-two percent of the decrease was achieved by 4 months. After 12 months, in the B 2 group the proportion of hyperhomocysteinemic participants decreased from 52 to 39% (P ¼ 0.02), in the B 10 group from 56 to 21% (Po0.000) and in the B 0 group it increased from 44 to 56% (P ¼ 0.02). Table 2 ). In the F 0 group, the proportion of hyperhomocysteinemic participants decreased from 53 to 44%, P ¼ 0.07 and in the F 200 group from 48 to 34%, P ¼ 0.003. Table 3 shows the number of hyperhomocysteinemic individuals in different supplementation groups who became normohomocysteinemic ('responded') or remained hyperhomocysteinemic ('not responded') after 12 months. The relative benefit of supplementation was similar in the two B 12 supplemented groups (B 2 and B 10 ), but was higher in the B 10 compared to the F 200 group. The number needed to treat was 4 for B 2 , 2 for B 10 and 10 for F 200 group. Abbreviation: NNT, number needed to treat. Responded, number of hyperhomocysteinemic participants who became normohomocysteinemic; not responded, number of hyperhomocysteinemic participants who remained hyperhomocysteinemic at the end of trial.
Side effects
There were 62 responses from 46 participants during the study period. One woman reported an accidental injury requiring hospital admission, which was not attributable to supplementation. Other responses were classified into positive (increased appetite, weight gain, sense of well-being; n ¼ 40) and negative (abdominal pain and acidity, feeling unwell; n ¼ 22). There was no obvious clustering of side effects in any particular intervention group.
Discussion
This is the first community-based randomized trial of B 12 supplementation in an Indian population with substantial B 12 deficiency due to low dietary intake. We found that both 2 and 10 mg per day of oral B 12 (cyanocobalamin) significantly reduced plasma tHcy concentrations in otherwise healthy, free-living, rural participants. Eighty-two percent of the effect was achieved by 4 months. Overall, the two doses of B 12 were similarly effective in reducing plasma tHcy concentrations. Folic acid by itself had no additional effect on plasma tHcy reduction, over placebo or in combination with B 12 (Table 2 in Supplementary Information).
The relatively large effect of such small doses of B 12 is probably related to the high prevalence of B 12 deficiency and hyperhomocysteinemia in this population (Refsum et al., 2001; Yajnik et al., 2006 Yajnik et al., , 2008 . Without B 12 supplementation, hyperhomocysteinemia increased by 12% over the 12-month period. Using the cut point of 15 mmol/l (adults) and 10 mmol/l (children), we found there was a 13% decrease in the hyperhomocysteinemia with 2 mg per day and 35% decrease with 10 mg per day of B 12 from the baseline. The large effect of supplementation was also evident in the small numbers needed to treat: only four hyperhomocysteinemic individuals needed to be treated with 2 mg per day of B 12 for 12 months, for one to become normohomocysteinemic and only two with 10 mg per day B 12 . If the relationship of maternal B 12 deficiency and hyperhomocysteinemia with fetal outcomes is causal B 12 intervention could translate into a substantial reduction in the incidence of LBW, diabetes and CVD in this community as well as improvement in cognitive function based on our previous findings (Yajnik et al., 2005 (Yajnik et al., , 2008 Bhate et al., 2008) .
Although we knew that B 12 deficiency was common in this population (Refsum et al., 2001; Yajnik et al., 2006 Yajnik et al., , 2008 , we used a placebo to maintain the scientific rigor and included an arm with only folic acid to test comparative effects, especially in view of proposed food fortification in India. Despite doubling of plasma folate concentrations, folic acid by itself had no effect on circulating tHcy concentrations; neither did it enhance the effect of B 12 (Figure 1 , Supplementary Information). This supports our contention that folate deficiency is not common in this population (Refsum et al., 2001; Yajnik et al., 2006 Yajnik et al., , 2008 . Although this dose of folic acid was not associated with any adverse effects over 12 months, the proposal for folic acid fortification in India for prevention of first occurrence neural tube defects (The Flour Fortification Initiative website, 2009) needs to be formally investigated, including co-fortification with B 12 .
The effect of supplementation on plasma tHcy was unrelated to the compliance (Table 1 in Supplementary  Information) , perhaps because the overall compliance was good (72%). Another explanation is that the dose of B 12 over 4 and 12 months was more than necessary to achieve the effect. This observation is reassuring for future public health interventions.
Major strengths of our study are that it was communitybased and included apparently healthy children and adults, rather than being targeted at high-risk groups or patients. The participation rate was high and compliance was maintained at high levels throughout the 12 months. The factorial design allowed us to look at independent effects of B 12 and folic acid in comparison to their combination and the placebo. We used physiological rather than pharmacological doses of vitamins, with a view to translate our findings into future public health programs. The difficulty in obtaining specially manufactured capsules led to a 5 months gap between the baseline data collection and commencement of the intervention. However, this was distributed similarly in different groups and therefore should not affect our results.
The striking reduction in plasma tHcy concentrations with small doses of 2 and 10 mg of B 12 merits discussion. In a recent study, we have shown that three doses of 2 mg of B 12 at 6 h intervals not only raised plasma B 12 concentrations but also caused a significant (though small) decrease in tHcy concentrations within 24 h of the first dose (Bhat et al., 2009) . This is perhaps a reflection of a B 12 -deficient state and high baseline plasma tHcy concentrations. The almost similar effect of 2 and 10 mg doses is perhaps related to characteristics of intestinal B 12 absorption, which is predominantly by an active (intrinsic factor-mediated) mechanism that saturates after a 1.5-2 mg dose (Carmel, 2008) . Only about 1% of absorption is by passive absorption (by diffusion).
In addition to these considerations, the duration of supplementation is also an important determinant of the effect. Small doses over a long time might be equally effective as a large dose over a short time (Carmel, 2008) . Our previous study (in vegetarian women) used a large dose of oral B 12 (500 mg every alternate day for 6 weeks) (Yajnik et al., 2007) . In 2 weeks (total dose 3 mg B 12 ) plasma tHcy concentrations decreased from 18.0 to 13.0 mmol/l, which remained static over the next 4 weeks (total dose 9 mg B 12 ). In this study, 0.72 mg of B 12 (2 mg per day Â 12 months) achieved a similar effect, 82% of which was achieved by 4 months with 0.24 mg B 12 .
The majority of published studies of B vitamin supplementation have been in predominantly nonvegetarian western populations, in whom folate deficiency is the main determinant of hyperhomocysteinemia (Selhub, 2008) . After folic acid fortification of foods in these populations, the
